Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor — OPTISAGE

GVHD Clinical Trial

Official title:
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Following a Reduced Intensity Conditioning Regimen by Fludarabine-treosulfan

Status Not yet recruiting

Clinical Trial Summary

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Most of the patients requiring an allo-HSCT are above 50 years of age and are transplanted with a reduced intensity conditioning (RIC) regimen. The optimal RIC and Graft Versus Host Disease (GVHD) prophylaxis regimen allowing a good control of the disease while preventing GVHD remains to be determined for elderly patients. A phase III trial comparing the conventional RIC fludarabine-busulfan 2 days to fludarabine-treosulfan demonstrated an advantage for the flu-treosulfan arm in terms of event free survival (EFS), that should therefore be considered as the new standard of RIC regimen for AML and MDS. GVHD prevention has a crucial role in post-transplant outcomes by potentially interfering with the graft-versus-leukemia (GVL) effect and immune reconstitution. Anti-thymocyte globulins (ATG) are recommended to reduce the risk of acute and chronic GVHD in transplants performed with matched unrelated donors. However, the optimal type of ATG between the 2 approved brands (ATG-thymoglobulin and ATLG-grafalon) displaying distinct characteristics and the optimal dose of ATG are still unknown. In a retrospective study of patients transplanted mainly with RIC with matched related and unrelated donors for haematological malignancies, we observed that Anti-T lymphocyte globulin (ATLG) was associated with a reduction of grade II-IV acute GVHD in comparison to ATG without increasing the incidence of relapse. In this phase III randomised study, we propose to compare GVHD prevention with ATG versus ATLG in AML and MDS patients above 50 years of age transplanted with a matched unrelated donor following a fludarabine-treosulfan RIC, with the hypothesis that ATLG would better control GVHD in this population of patients thus limiting the risk of morbidity and mortality of the procedure.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06083129
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact	Régis Peffault de Latour, Pr
Phone	+33142385073
Email	regis.peffaultdelatour@aphp.fr
Status	Not yet recruiting
Phase	Phase 3
Start date	November 1, 2023
Completion date	November 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02942173` - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT	Phase 2/Phase 3
Completed	`NCT02066051` - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD	N/A
Terminated	`NCT01940796` - Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)	Phase 1
Not yet recruiting	`NCT05544448` - In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases	N/A
Completed	`NCT01295710` - Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)	Phase 3
Not yet recruiting	`NCT06075225` - MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib	Phase 2
Not yet recruiting	`NCT06000982` - Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis	Phase 3
Active, not recruiting	`NCT03680092` - Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation	Phase 2
Not yet recruiting	`NCT05094765` - Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD	Early Phase 1
Active, not recruiting	`NCT05415410` - Proof-of-concept Trial of Apraglutide in GVHD	Phase 2
Completed	`NCT02441075` - 70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014	N/A
Completed	`NCT02588339` - Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention	Phase 2
Not yet recruiting	`NCT06334367` - Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT	Phase 2
Completed	`NCT03846479` - Itacitinib for Low Risk GVHD	Phase 2
Completed	`NCT02891603` - A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression	Phase 1/Phase 2
Completed	`NCT02712762` - Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
Completed	`NCT03945591` - High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	Phase 2
Not yet recruiting	`NCT06411184` - Safety and Efficacy of Treg Cell in the Treatment of GVHD	Phase 1/Phase 2
Terminated	`NCT02338232` - Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT02156479` - Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients